Molbio Diagnostics Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDHealthcare
This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.
PROS
- Operating margins have improved to 22.2% from 13.0%
- Company comfortably covers its interest (7.9x coverage)
- Company maintains a comfortable, low leverage position
CONS
- Equity base is being diluted - shares outstanding up 400.3%
- Total debt has risen sharply - up 235.0% year on year
- Recurring exceptional / one-off items are inflating headline profit
- Though reporting repeated profits, the company pays out little dividend (0.0%)
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| LENSKART | 694.05 | 184.20 | 120716.54 | 0.00 | 2284.30 | 3634.35 | 27141.80 | 1332.69 | 12.55 | 21.70 |
| POLYMED | 1723.80 | 55.45 | 17472.69 | 0.20 | 85.27 | -8.39 | 525.38 | 30.30 | 14.05 | 24.11 |
| MOLBIO | 1258.10 | 87.03 | 14498.34 | 0.00 | 527.44 | — | 4083.76 | — | 19.79 | 24.63 |
| 3BBLACKBIO | 1472.10 | 22.75 | 1263.45 | 0.34 | 8.98 | -28.99 | 33.49 | 50.59 | 26.03 | 25.45 |
| LAXMIDENTL | 200.40 | 35.70 | 1102.79 | 0.00 | 10.32 | 23.83 | 74.70 | 16.13 | 24.96 | 20.26 |
| GKB | 66.13 | 10.28 | 33.33 | 0.00 | 1.85 | 387.99 | 33.04 | 2.26 | 8.82 | 7.97 |
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Jun 2025 | Jun 2026 | |
|---|---|---|
| 100 | 4,084 | |
| 131 | 3,356 | |
| Operating Profit | -31 | 728 |
| OPM % | -31.28% | 17.83% |
| 1 | 31 | |
| Interest | 4 | 107 |
| Depreciation | 12 | 171 |
| Profit before Tax | -31 | 759 |
| Tax % | 23.45% | 30.52% |
| Net Profit | -24 | 527 |
| -2.10 | 5.21 |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 332 | 837 | 1,020 | 1,446 | |
| 289 | 602 | 758 | 1,124 | |
| Operating Profit | 43 | 234 | 262 | 321 |
| OPM % | 12.98% | 27.99% | 25.70% | 22.23% |
| 5 | -49 | -4 | 9 | |
| Interest | 7 | 14 | 18 | 33 |
| Depreciation | 32 | 41 | 45 | 64 |
| Profit before Tax | 10 | 130 | 194 | 231 |
| Tax % | 136.11% | 35.56% | 28.72% | 28.99% |
| Net Profit | -3 | 84 | 139 | 164 |
| EPS | -3.22 | 452.32 | 64.32 | 14.77 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
COMPOUNDED SALES GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 63%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- —
- 1 Year:
- —
RETURN ON EQUITY
- 10 Years:
- —
- 5 Years:
- —
- 3 Years:
- 14%
- Last Year:
- 15%
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 11 |
| Minority Interest | 16 | 5 | -1 | 139 |
| 719 | 821 | 966 | 1,158 | |
| 138 | 193 | 154 | 420 | |
| Trade Payables | 86 | 94 | 230 | 200 |
| 63 | 76 | 63 | 169 | |
| Total Liabilities | 1,024 | 1,192 | 1,415 | 2,097 |
| 286 | 256 | 290 | 536 | |
| Capital Work in Progress | 0 | 2 | 27 | 11 |
| 6 | 6 | 46 | 6 | |
| 347 | 315 | 436 | 449 | |
| 189 | 425 | 272 | 409 | |
| Cash & Bank | 7 | 22 | 129 | 367 |
| 189 | 165 | 216 | 318 | |
| Total Assets | 1,024 | 1,192 | 1,415 | 2,097 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 64 | 10 | 287 | 50 | |
| Cash from Investing | -40 | -45 | -123 | -93 |
| Cash from Financing | 18 | -32 | -26 | 276 |
| 43 | -67 | 138 | 233 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-09-09 - Molbio Diagnostics Limited has informed the Exchange regarding Intimation regarding change of Corporate Identification Number (CIN) of the Company.
2026-09-08 - Molbio Diagnostics Limited has informed the Exchange about Link of Recording
2026-09-08 - Molbio Diagnostics Limited has informed the Exchange about Investor Presentation on the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026
2026-09-07 - Molbio Diagnostics Limited has informed the Exchange about Copy of Newspaper Publication of Un-audited Financial Results for the quarter ended June 30, 2026.
2026-09-07 - Molbio Diagnostics Limited has informed the Exchange regarding a press release dated September 07, 2026, titled "Press Release for the Quarter ended June 30, 2026.".
2026-09-05 - Molbio Diagnostics Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-09-02 - Molbio Diagnostics Limited has informed the Exchange that an Earnings Conference Call is scheduled on Tuesday, 08th September 2026 at 04.00 P.M. IST to discuss the financial performance of the Company for the quarter ended June 30, 2026.
2026-08-27 - Molbio Diagnostics Limited has informed the Exchange regarding Outcome of Board Meeting held on August 27, 2026.
2026-08-20 - Molbio Diagnostics Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
News
Recent coverage and analyst commentary for MOLBIO
Loading news…
AI Stock Analyst
Molbio Diagnostics Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account